FDA-approved kinase inhibitors in PROTAC design, development and synthesis
FDA-approved kinase inhibitors represent a rapidly growing class of targeted therapies with proven clinical success in oncology. However, their occupancy-driven mode of action is often associated with resistance, off-target effects, and incomplete inhibition. Proteolysis-Targeting Chimaeras (PROTACs...
I tiakina i:
| Ngā kaituhi matua: | , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Taylor & Francis Group
2025-12-01
|
| Rangatū: | Journal of Enzyme Inhibition and Medicinal Chemistry |
| Ngā marau: | |
| Urunga tuihono: | https://www.tandfonline.com/doi/10.1080/14756366.2025.2542357 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|